ESR1 and breast cancer: The effect of calcitriol and EB1089 as monotherapies on cell proliferation, UPR, and autophagy was studied in LCC1 (TAM-sensitive) and LCC9 (TAM-resistant) human ER+ breast cancer cell lines.